Mirabegron
Brand names: Mirabegron Er, Myrbetriq
At a glance
- Medicare prescriptions, 2024
- 3,061,728
- Medicare drug cost
- $1.93B
- Average cost per prescription
- $631
- Clinicians who prescribed it
- 68,418
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more.
From the FDA-approved prescribing information (label dated July 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Urology 25.1%
- Family Medicine 19.0%
- Internal Medicine 17.7%
- Nurse Practitioners 17.6%
- Physician Assistants 9.3%
- Urogynecology 3.7%
- OB-GYN (Obstetrics & Gynecology) 2.4%
- Geriatric Medicine 2.0%
- General Practice 0.6%
- Hospitalist 0.4%
- Neurology 0.3%
- Nephrology (Kidney) 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 34% from 2019 to 2024.
Biggest change by state since 2019
- Minnesota +105%
- New Mexico +90%
- Utah +80%
- Rhode Island +77%
- Michigan +73%
- Connecticut (smallest change) +12%
- Mississippi (smallest change) +13%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Ascend Laboratories, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 8 mg | yellow for suspension | |
Astellas Pharma US, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 8 mg | yellow granule | |
| 25 mg | brown oval tablet, 12 mm | ASTELLAS LOGO 325 |
| 50 mg | yellow oval tablet, 12 mm | ASTELLAS LOGO 355 |
Avkare
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | brown oval tablet, 12 mm | 25 M |
| 50 mg | yellow oval tablet, 12 mm | 50 M |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | yellow oval tablet, 12 mm | 1160 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $8,182 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Astellas Pharma Global Development $7,862
- Astellas Pharma US Inc $320
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Aug 2026 · Zydus Pharmaceuticals (USA) Inc · Class II
CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.